Esperion (ESPR) launched a press launch at this time stating that their part 3 CLEAR research met its main endpoint (mortality advantage of not less than 15%) but the inventory was down 15%. I do not get why. And earlier than anybody says {that a} constructive trial end result was already “baked” in to the inventory value, that clearly wasn’t the case right here. The drug and firm have struggled since preliminary FDA approval in 2020.
https://www.globenewswire.com/news-release/2022/12/07/2569280/0/en/Esperion-Declares-CLEAR-Cardiovascular-Outcomes-Trial-of-NEXLETOL-bempedoic-acid-Meets-Major-Endpoint.html
